Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 25, 2006 Stephen D. Simpson	An Eye-Opening Quarter at Alcon Good news may have been overdue from the eye-care company, but the jubilation seems overdone. Investors, take note.
The Motley Fool October 20, 2005 Stephen D. Simpson	Wide Eyes at Alcon Excellent margin performance fueled exceptional growth for this eye-care titan. This is a strong and valuable cash-producing franchise, and it deserves a premium valuation -- but how much of a premium?
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
The Motley Fool August 7, 2006 Stephen D. Simpson	Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues.
The Motley Fool February 11, 2005 Stephen D. Simpson	For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant.
The Motley Fool April 19, 2005 Stephen D. Simpson	Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note.
The Motley Fool November 2, 2005 Stephen D. Simpson	AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note.
The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool April 22, 2004 Brian Gorman	Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving.
The Motley Fool October 27, 2005 Brian Gorman	Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool June 7, 2006 Stephen D. Simpson	Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse.
BusinessWeek January 7, 2010 Capell & Doherty	What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business.
The Motley Fool May 31, 2007 Billy Fisher	Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note.
The Motley Fool January 29, 2009 Brian Orelli	Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed.
The Motley Fool January 4, 2010 Brian Orelli	You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon.
The Motley Fool July 21, 2006 Stephen D. Simpson	Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool July 5, 2005 Brian Gorman	Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool July 22, 2004 Nathan Slaughter	VISX Eyes Future The vision-correction firm posts triple-digit earnings growth, capturing the attention of investors.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
The Motley Fool February 27, 2007 Billy Fisher	OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note.
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool April 11, 2006 Rick Aristotle Munarriz	Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news.
The Motley Fool August 10, 2010 Seth Jayson	Marginal Performance at Alcon The more Alcon keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.
The Motley Fool February 21, 2006 Stephen D. Simpson	A Little Sand in the EYE Advanced Medical Optics' transition effort looks messy, but should pay off later this year. Investors need to monitor a few key issues here, though.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool July 29, 2008 Dan Dzombak	3 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: Varian Medical Systems... Alcon... Amgen...
The Motley Fool January 27, 2010 Brian Orelli	Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool January 20, 2010 Brian Orelli	Those Are Fighting Words Alcon's minority shareholders fight back.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool August 10, 2010 David Meier	Would Jeremy Grantham Buy Alcon? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains.
The Motley Fool August 18, 2010 David Meier	Alcon: Deflation Fighter Alcon could be a good candidate to keep you ahead of the game.
The Motley Fool May 31, 2005 Karl Thiel	Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.
The Motley Fool August 24, 2010 David Meier	Could Alcon Be a Multibagger? Strong returns on equity can generate powerful shareholder returns.
The Motley Fool June 28, 2010 Brian Orelli	The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover.
The Motley Fool May 17, 2007 Matt Koppenheffer	Bausch & Lomb: How Much Is Too Much? Private equity's Warburg Pincus agrees to take the eye-care company private. Investors, take note.
BusinessWeek May 7, 2007 Gene G. Marcial	A Closer Look At Cooper Turnaround efforts and a search for a new chief at Cooper, whose coopervision arm makes contact lenses, have wall street in a wait-and-see stance.
The Motley Fool August 5, 2010 Seth Jayson	Show Me the Money, Alcon With questionable cash sources comprising 4% of the cash flow from operations for Alcon, I am pretty confident things are OK.